Welcome to our dedicated page for Phathom Pharmaceuticals SEC filings (Ticker: PHAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Phathom Pharmaceuticals, Inc. filings document financial reporting, governance, capital structure and product-development disclosures for a Nasdaq-listed biopharmaceutical company focused on gastrointestinal diseases. Form 8-K reports include quarterly and annual results, preliminary financial information, material agreements, financing-related updates, and other event disclosures tied to VOQUEZNA® commercialization and clinical development.
Proxy materials cover board matters, executive compensation, equity awards and shareholder voting items. The filing record also describes registered common stock, risk-oriented forward-looking statements, and clinical or publication updates involving VOQUEZNA in GERD, non-erosive reflux disease and eosinophilic esophagitis.
Phathom Pharmaceuticals director Asit Parikh exercised stock options to acquire 8,750 shares of common stock. On 01/13/2026, he converted 8,750 derivative securities labeled as Common Stock (Right to Buy) at an exercise price of $10.30 per share into 8,750 shares of Phathom common stock in a transaction coded "M" (option exercise).
Following this transaction, Parikh directly beneficially owned 131,000 shares of Phathom Pharmaceuticals common stock. The filing does not show any sale of shares in connection with this option exercise; it simply reflects the option conversion and updated direct ownership.
Phathom Pharmaceuticals is raising capital through an underwritten public offering of 6,875,000 shares of common stock at $16.00 per share and pre-funded warrants to purchase 1,250,078 shares at $15.999 per warrant. The underwriters also have a 30-day option to buy up to 1,218,761 additional shares at the public price, less discounts and commissions.
The company expects to receive approximately $130 million in net proceeds from the offering, or about $150 million if the option is fully exercised, before fees and expenses. The pre-funded warrants have a $0.001 exercise price, are immediately exercisable, do not expire, and include a beneficial ownership cap of up to 19.99% of outstanding common stock, which holders can adjust within that limit subject to notice.
Phathom Pharmaceuticals is offering 6,875,000 shares of common stock and pre‑funded warrants to purchase 1,250,078 shares, at public prices of $16.00 per share and $15.999 per pre‑funded warrant. This underwritten offering is expected to generate gross proceeds of $129,999,998 and estimated net proceeds of about $121.7 million, with an underwriters’ option for 1,218,761 additional shares that could lift net proceeds to about $140.0 million. The company plans to use the cash for general corporate purposes, including working capital plus commercialization and R&D spending for its VOQUEZNA gastrointestinal products.
Phathom highlights having surpassed one million VOQUEZNA prescriptions dispensed in the United States since launch and currently anticipates reaching operating profitability in the second half of 2026, excluding stock‑based compensation. The filing cautions investors about immediate and substantial dilution from buying at $16.00 compared with a negative net tangible book value, and notes that pre‑funded warrants provide only nominal additional cash on exercise and will not have a trading market.
Phathom Pharmaceuticals is launching an underwritten public offering of common stock and pre-funded warrants. Certain investors can buy pre-funded warrants instead of shares, each with a $0.001 per-share exercise price and a 19.99% ownership cap to limit concentration. The company plans to use the net proceeds for general corporate purposes, including working capital plus commercialization and research and development spending.
Phathom reports that VOQUEZNA products have surpassed one million prescriptions dispensed in the United States since launch, highlighting growing GI franchise usage. Based on current plans, it anticipates achieving operating profitability in the second half of 2026, excluding stock-based compensation. New buyers face immediate dilution because the offering price will be above the company’s negative net tangible book value as of September 30, 2025.
Phathom Pharmaceuticals, Inc. filed a current report to disclose that it has issued a press release with certain preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025. The company states that this press release, dated January 7, 2026, is included as an exhibit and incorporated by reference into its securities law filings, making the early 2025 figures part of its official disclosure record.
Phathom Pharmaceuticals has registered 5,827,415 shares of common stock for potential resale by a large stockholder, with all sale proceeds going to that holder rather than the company.
Separately, as a well-known seasoned issuer, Phathom has filed an automatic shelf registration on Form S-3 that allows it to offer common stock, preferred stock, debt securities, warrants and units from time to time, with specific terms and uses of proceeds to be detailed in future prospectus supplements.
The company focuses on gastrointestinal treatments built around vonoprazan, the active ingredient in its VOQUEZNA-branded products for conditions such as erosive GERD and H. pylori infection.
Phathom Pharmaceuticals, Inc. reported an equity award transaction for its President, CEO and Director, Steven L. Basta. On January 2, 2026, he received 251,034 restricted stock units (RSUs) of common stock at a price of $0 per share, increasing his directly held common stock to 364,820 shares after the transaction. Each RSU represents a right to receive one share of common stock.
The RSUs vest over three years, with one-third of the award vesting on each of the first three anniversaries of January 2, 2026, subject to his continued service. On the same date, he was also granted a stock option to purchase 226,156 shares of common stock at an exercise price of $15.71 per share, expiring on January 1, 2036. One forty-eighth of the option vests monthly following the vesting commencement date, conditioned on his continuous service.
Phathom Pharmaceuticals, Inc. President and CEO Steven L. Basta exercised 90,000 performance stock units, receiving an equal number of common shares on November 28, 2025. In connection with this vesting, 48,375 shares were delivered to the issuer at $15.62 per share to satisfy tax withholding obligations. After these transactions, he held 83,250 shares of common stock directly. A grant on April 3, 2025 covered 360,000 performance stock units, of which 90,000 vested on September 25, 2025 and another 90,000 on November 28, 2025; remaining units vest upon achievement of stock price hurdles over four years.
Phathom Pharmaceuticals (PHAT) insider filing: The company’s Principal Accounting Officer reported a sale of common stock on 11/03/2025. The filing shows 524 shares sold at $13.51 (transaction code S).
The footnote states the shares were sold to satisfy tax withholding obligations upon the settlement of restricted stock units. Following the transaction, beneficial ownership stands at 47,407 shares held directly and 6,945.4 shares held indirectly via a 401(k).
Phathom Pharmaceuticals announced the first patient has been dosed in its Phase 2 pHalcon EoE-201 trial evaluating VOQUEZNA (vonoprazan) tablets as an investigational treatment for eosinophilic esophagitis in adults.
The study is a two-part, randomized, double-blind, placebo-controlled trial. Part 1 will enroll 80 adults with endoscopic-confirmed EoE and dysphagia, randomized to VOQUEZNA 20 mg or placebo once daily for 12 weeks. Patients who complete Part 1 may enter a 12-week extension (Part 2), where all participants receive VOQUEZNA 20 mg.
Topline primary and secondary results are anticipated in 2027. The company also noted typical development uncertainties and forward-looking risks related to study conduct, enrollment, outcomes, and future program decisions.